Prelude Capital Management, LLC Aligos Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

  • $1.57 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$1.04 - $2.14 $28,184 - $57,994
-27,100 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$2.08 - $12.2 $56,368 - $330,620
27,100 New
27,100 $58,000

Others Institutions Holding ALGS

# of Institutions
1
Shares Held
227K
Call Options Held
0
Put Options Held
0
View Full List

About Aligos Therapeutics, Inc.

ALGS Quotes by TradingView
  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $1.3B
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email